BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27898666)

  • 1. Algorithm Optimization in Methylation Detection with Multiple RT-qPCR.
    Song L; Li Y; Jia J; Zhou G; Wang J; Kang Q; Jin P; Sheng J; Cai G; Cai S; Han X
    PLoS One; 2016; 11(11):e0163333. PubMed ID: 27898666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epi proColon
    Lamb YN; Dhillon S
    Mol Diagn Ther; 2017 Apr; 21(2):225-232. PubMed ID: 28155091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location.
    Song L; Jia J; Yu H; Peng X; Xiao W; Gong Y; Zhou G; Han X; Li Y
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1093-1101. PubMed ID: 28224298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Colorectal Cancer Using a Simplified SEPT9 Gene Methylation Assay Is a Reliable Method for Opportunistic Screening.
    Wu D; Zhou G; Jin P; Zhu J; Li S; Wu Q; Wang G; Sheng J; Wang J; Song L; Han X; Qian J
    J Mol Diagn; 2016 Jul; 18(4):535-45. PubMed ID: 27133379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epi proColon
    Shirley M
    Mol Diagn Ther; 2020 Aug; 24(4):497-503. PubMed ID: 32557236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SEPT9 gene methylation assay is capable of detecting colorectal adenoma in opportunistic screening.
    Song L; Peng X; Li Y; Xiao W; Jia J; Dong C; Gong Y; Zhou G; Han X
    Epigenomics; 2017 May; 9(5):599-610. PubMed ID: 28470092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study.
    Ørntoft MB; Nielsen HJ; Ørntoft TF; Andersen CL;
    BMC Cancer; 2015 Oct; 15():819. PubMed ID: 26514170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma.
    Potter NT; Hurban P; White MN; Whitlock KD; Lofton-Day CE; Tetzner R; Koenig T; Quigley NB; Weiss G
    Clin Chem; 2014 Sep; 60(9):1183-91. PubMed ID: 24938752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis.
    Song L; Jia J; Peng X; Xiao W; Li Y
    Sci Rep; 2017 Jun; 7(1):3032. PubMed ID: 28596563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma methylated septin 9: a colorectal cancer screening marker.
    Molnár B; Tóth K; Barták BK; Tulassay Z
    Expert Rev Mol Diagn; 2015 Feb; 15(2):171-84. PubMed ID: 25429690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A robust internal control for high-precision DNA methylation analyses by droplet digital PCR.
    Pharo HD; Andresen K; Berg KCG; Lothe RA; Jeanmougin M; Lind GE
    Clin Epigenetics; 2018; 10():24. PubMed ID: 29484034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis.
    Song L; Yu H; Jia J; Li Y
    Cancer Biomark; 2017; 18(4):425-432. PubMed ID: 28128742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The quantitative profiling of blood mSEPT9 determines the detection performance on colorectal tumors.
    Song L; Wang J; Wang H; Chen Y; Jia J; Guo S; Liu H; Peng X; Xiao W; Gong Y; Yang B; Lu Y; Li Y
    Epigenomics; 2018 Dec; 10(12):1569-1583. PubMed ID: 30426784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous Analysis of SEPT9 Promoter Methylation Status, Micronuclei Frequency, and Folate-Related Gene Polymorphisms: The Potential for a Novel Blood-Based Colorectal Cancer Biomarker.
    Ravegnini G; Zolezzi Moraga JM; Maffei F; Musti M; Zenesini C; Simeon V; Sammarini G; Festi D; Hrelia P; Angelini S
    Int J Mol Sci; 2015 Dec; 16(12):28486-97. PubMed ID: 26633373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer.
    He Q; Chen HY; Bai EQ; Luo YX; Fu RJ; He YS; Jiang J; Wang HQ
    Cancer Genet Cytogenet; 2010 Oct; 202(1):1-10. PubMed ID: 20804913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer.
    Tham C; Chew M; Soong R; Lim J; Ang M; Tang C; Zhao Y; Ong SY; Liu Y
    Cancer; 2014 Oct; 120(20):3131-41. PubMed ID: 24925595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation biomarkers for blood-based colorectal cancer screening.
    Lofton-Day C; Model F; Devos T; Tetzner R; Distler J; Schuster M; Song X; Lesche R; Liebenberg V; Ebert M; Molnar B; Grützmann R; Pilarsky C; Sledziewski A
    Clin Chem; 2008 Feb; 54(2):414-23. PubMed ID: 18089654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of colorectal cancer by DNA methylation biomarker SEPT9: past, present and future.
    Li Y; Song L; Gong Y; He B
    Biomark Med; 2014; 8(5):755-69. PubMed ID: 25123042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA Methylation Analysis of Free-Circulating DNA in Body Fluids.
    Jung M; Kristiansen G; Dietrich D
    Methods Mol Biol; 2018; 1708():621-641. PubMed ID: 29224167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.